D-amino-acid oxidase inhibition increases D-serine plasma levels in mouse but not in monkey or dog

Camilo Rojas, Jesse Alt, Nancy A Ator, Ajit G. Thomas, Ying Wu, Niyada Hin, Krystyna Wozniak, Dana Ferraris, Rana Rais, Takashi Tsukamoto, Barbara Slusher

Research output: Contribution to journalArticle

Abstract

D-serine has been shown to improve positive, negative, and cognitive symptoms when used as add-on therapy for the treatment of schizophrenia. However, D-serine has to be administered at high doses to observe clinical effects. This is thought to be due to D-serine undergoing oxidation by D-amino-acid oxidase (DAAO) before it reaches the brain. Consequently, co-administration of D-serine with a DAAO inhibitor could be a way to lower the D-serine dose required to treat schizophrenia. Early studies in rodents to evaluate this hypothesis showed that concomitant administration of structurally distinct DAAO inhibitors with D-serine enhanced plasma and brain D-serine levels in rodents compared with administration of D-serine alone. In the present work we used three potent DAAO inhibitors and confirmed previous results in mice. In a follow-up effort, we evaluated plasma D-serine levels in monkeys after oral administration of D-serine in the presence or absence of these DAAO inhibitors. Even though the compounds reached steady state plasma concentrations exceeding their K i values by >60-fold, plasma D-serine levels remained the same as those in the absence of DAAO inhibitors. Similar results were obtained with dogs. In summary, in contrast to rodents, DAAO inhibition in monkeys and dogs did not influence the exposure to exogenously administered D-serine. Results could be due to differences in D-serine metabolism and/or clearance mechanisms and suggest that the role of DAAO in the metabolism of D-serine is different across species. These data provide caution regarding the utility of DAAO inhibition for patients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)1610-1619
Number of pages10
JournalNeuropsychopharmacology
Volume41
Issue number6
DOIs
StatePublished - May 1 2016

Fingerprint

D-Amino-Acid Oxidase
Serine
Haplorhini
Dogs
Rodentia
Schizophrenia
Inhibition (Psychology)
Neurobehavioral Manifestations
Brain

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

D-amino-acid oxidase inhibition increases D-serine plasma levels in mouse but not in monkey or dog. / Rojas, Camilo; Alt, Jesse; Ator, Nancy A; Thomas, Ajit G.; Wu, Ying; Hin, Niyada; Wozniak, Krystyna; Ferraris, Dana; Rais, Rana; Tsukamoto, Takashi; Slusher, Barbara.

In: Neuropsychopharmacology, Vol. 41, No. 6, 01.05.2016, p. 1610-1619.

Research output: Contribution to journalArticle

Rojas, Camilo ; Alt, Jesse ; Ator, Nancy A ; Thomas, Ajit G. ; Wu, Ying ; Hin, Niyada ; Wozniak, Krystyna ; Ferraris, Dana ; Rais, Rana ; Tsukamoto, Takashi ; Slusher, Barbara. / D-amino-acid oxidase inhibition increases D-serine plasma levels in mouse but not in monkey or dog. In: Neuropsychopharmacology. 2016 ; Vol. 41, No. 6. pp. 1610-1619.
@article{8bb4b493ad5a4a68ba55e515e461494f,
title = "D-amino-acid oxidase inhibition increases D-serine plasma levels in mouse but not in monkey or dog",
abstract = "D-serine has been shown to improve positive, negative, and cognitive symptoms when used as add-on therapy for the treatment of schizophrenia. However, D-serine has to be administered at high doses to observe clinical effects. This is thought to be due to D-serine undergoing oxidation by D-amino-acid oxidase (DAAO) before it reaches the brain. Consequently, co-administration of D-serine with a DAAO inhibitor could be a way to lower the D-serine dose required to treat schizophrenia. Early studies in rodents to evaluate this hypothesis showed that concomitant administration of structurally distinct DAAO inhibitors with D-serine enhanced plasma and brain D-serine levels in rodents compared with administration of D-serine alone. In the present work we used three potent DAAO inhibitors and confirmed previous results in mice. In a follow-up effort, we evaluated plasma D-serine levels in monkeys after oral administration of D-serine in the presence or absence of these DAAO inhibitors. Even though the compounds reached steady state plasma concentrations exceeding their K i values by >60-fold, plasma D-serine levels remained the same as those in the absence of DAAO inhibitors. Similar results were obtained with dogs. In summary, in contrast to rodents, DAAO inhibition in monkeys and dogs did not influence the exposure to exogenously administered D-serine. Results could be due to differences in D-serine metabolism and/or clearance mechanisms and suggest that the role of DAAO in the metabolism of D-serine is different across species. These data provide caution regarding the utility of DAAO inhibition for patients with schizophrenia.",
author = "Camilo Rojas and Jesse Alt and Ator, {Nancy A} and Thomas, {Ajit G.} and Ying Wu and Niyada Hin and Krystyna Wozniak and Dana Ferraris and Rana Rais and Takashi Tsukamoto and Barbara Slusher",
year = "2016",
month = "5",
day = "1",
doi = "10.1038/npp.2015.319",
language = "English (US)",
volume = "41",
pages = "1610--1619",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - D-amino-acid oxidase inhibition increases D-serine plasma levels in mouse but not in monkey or dog

AU - Rojas, Camilo

AU - Alt, Jesse

AU - Ator, Nancy A

AU - Thomas, Ajit G.

AU - Wu, Ying

AU - Hin, Niyada

AU - Wozniak, Krystyna

AU - Ferraris, Dana

AU - Rais, Rana

AU - Tsukamoto, Takashi

AU - Slusher, Barbara

PY - 2016/5/1

Y1 - 2016/5/1

N2 - D-serine has been shown to improve positive, negative, and cognitive symptoms when used as add-on therapy for the treatment of schizophrenia. However, D-serine has to be administered at high doses to observe clinical effects. This is thought to be due to D-serine undergoing oxidation by D-amino-acid oxidase (DAAO) before it reaches the brain. Consequently, co-administration of D-serine with a DAAO inhibitor could be a way to lower the D-serine dose required to treat schizophrenia. Early studies in rodents to evaluate this hypothesis showed that concomitant administration of structurally distinct DAAO inhibitors with D-serine enhanced plasma and brain D-serine levels in rodents compared with administration of D-serine alone. In the present work we used three potent DAAO inhibitors and confirmed previous results in mice. In a follow-up effort, we evaluated plasma D-serine levels in monkeys after oral administration of D-serine in the presence or absence of these DAAO inhibitors. Even though the compounds reached steady state plasma concentrations exceeding their K i values by >60-fold, plasma D-serine levels remained the same as those in the absence of DAAO inhibitors. Similar results were obtained with dogs. In summary, in contrast to rodents, DAAO inhibition in monkeys and dogs did not influence the exposure to exogenously administered D-serine. Results could be due to differences in D-serine metabolism and/or clearance mechanisms and suggest that the role of DAAO in the metabolism of D-serine is different across species. These data provide caution regarding the utility of DAAO inhibition for patients with schizophrenia.

AB - D-serine has been shown to improve positive, negative, and cognitive symptoms when used as add-on therapy for the treatment of schizophrenia. However, D-serine has to be administered at high doses to observe clinical effects. This is thought to be due to D-serine undergoing oxidation by D-amino-acid oxidase (DAAO) before it reaches the brain. Consequently, co-administration of D-serine with a DAAO inhibitor could be a way to lower the D-serine dose required to treat schizophrenia. Early studies in rodents to evaluate this hypothesis showed that concomitant administration of structurally distinct DAAO inhibitors with D-serine enhanced plasma and brain D-serine levels in rodents compared with administration of D-serine alone. In the present work we used three potent DAAO inhibitors and confirmed previous results in mice. In a follow-up effort, we evaluated plasma D-serine levels in monkeys after oral administration of D-serine in the presence or absence of these DAAO inhibitors. Even though the compounds reached steady state plasma concentrations exceeding their K i values by >60-fold, plasma D-serine levels remained the same as those in the absence of DAAO inhibitors. Similar results were obtained with dogs. In summary, in contrast to rodents, DAAO inhibition in monkeys and dogs did not influence the exposure to exogenously administered D-serine. Results could be due to differences in D-serine metabolism and/or clearance mechanisms and suggest that the role of DAAO in the metabolism of D-serine is different across species. These data provide caution regarding the utility of DAAO inhibition for patients with schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=84963499869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963499869&partnerID=8YFLogxK

U2 - 10.1038/npp.2015.319

DO - 10.1038/npp.2015.319

M3 - Article

C2 - 26471255

AN - SCOPUS:84963499869

VL - 41

SP - 1610

EP - 1619

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 6

ER -